IL1B and atherosclerosis: Subsequently, the Colchicine Cardiovascular Outcomes Trial (COLCOT) and Low-Dose Colchicine 2 trial (LoDoCo2) showed that treatment with colchicine, an anti-inflammatory medication that targets the NLRP3 inflammasome/IL-1β-IL-6 axis, also leads to fewer cardiac events in patients with known ASCVD [42,43].